Navigation Links
Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand
Date:12/19/2007

- Neptune Technologies & Bioressources Inc. enters into an exclusive distribution agreement with AZPA International Inc. for Australia and New

Zealand -

LAVAL, QC, Dec. 19 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has entered into an exclusive distribution agreement with AZPA International Inc. ("AZPA International") for Australia and New Zealand. AZPA International, a leading supplier to the pharmaceutical, nutritional health and cosmetics industries, has also acquired non-exclusive rights to commercialize Neptune's products in Southeast Asia and Hong Kong.

The nationwide product launch of Neptune Krill Oil (NKO(R)) in Australia and New Zealand, claiming cardiovascular and joint health benefits, is scheduled for February 2008. A pre-requisite for commercializing NKO(R) in Australia hence New Zealand is obtaining approval as a complementary medicine from the Therapeutic Goods Administration (TGA) which notification Neptune has recently announced.

AZPA International joined forces for the commercialization and distribution of NKO(R) with PharmaLink Pte. Ltd. ("PharmaLink"), a leading provider of complementary and over-the-counter medicines and a leader in healthcare sales and marketing in the Asia-Pacific region. PharmaLink will be reaching the market through its primary care team, its pharmacy/ OTC team and its specialist/ allied health team.

"It is estimated that 74% of the Australian population has used complementary medicine in the previous twelve months and usage rates are expected to rise,(1)" said Thierry Houillon, Vice President of Nutraceuticals of Neptune. "An estimated annual increase of 18% has been reported for the complementary medicine market in Australia.(2) We are looking forward to working with AZPA International and PharmaLink benefiting from this trend and making NKO(R) a household name in Australia and New Zealand," he added.

PharmaLink, in collaboration with AZPA International, will also prepare a comprehensive marketing campaign, including medical conventions, tradeshows, and extensive press and mass media coverage. Selected consumers will be taking NKO(R) for a period of three months and will subsequently be reporting on radio & TV talk shows about their experience with NKO(R).

In addition, AZPA International will be working with Lipa Pharmaceuticals, Australia's leading contract manufacturer to the nutritional and pharmaceutical industries, which makes products in key growth areas of complementary and alternative medicines, over-the-counter (OTC) and prescription pharmaceuticals.

1. Source: Cardinal Health. Vitamin, Mineral, Herbal and Nutritional

Supplements, 4 October 2005

2. Source: Complementary Healthcare Council communication, 13 September

2005.

About Neptune Technologies & Bioressources Inc.

Neptune develops proprietary health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, the Company is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neptune continues to strongly support its strategic development plan to form partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. Neptune has recently signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, paving its entrance into the global functional food market. According to its business strategy, negotiations with pharmaceutical companies with the objective of entering the pharmaceutical market by licensing rights are ongoing.

NASDAQ and TSX venture exchange does not accept responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted
2. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
3. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
4. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Horses Helping Horses' donation level ... charity, it not only donates 15%-20% of each sale to Brooke USA , ... factory-permitted prices. , At inception, over 50 brands comprising over 2,700 items are represented, ...
(Date:12/9/2016)... , ... December 09, 2016 , ... There’s a winning ... 2016 by the Orange County Register, after winning the award last year as well. ... sought-after employer. President and COO Daniel Vesely pointed to the tech company’s upbeat environment ...
(Date:12/9/2016)... NEW YORK (PRWEB) , ... December 09, 2016 , ... ... have been honored with the Breakthrough Solution of the Year Award from Platts ... dicarboxylic methyl ester (FDME). The award was announced at the 18th Platts Global ...
(Date:12/9/2016)... ... ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, is pleased ... now gaining interest from Silicon Valley. “It was satisfying to complete the due diligence ... that, “We expect interest to continue to rise as AxioMed completes its cleanroom assembly ...
Breaking Biology Technology:
(Date:12/8/2016)... Research Future published a half cooked research report on Mobile Biometric ... Market is expected to grow over the CAGR of ~35% during ... ... Mobile Biometric Security and Service Market is increasing at a ... security from unwanted cyber threats. The increasing use of mobile device ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):